Tag: SAHARA Trial

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare  technology company focused on creating innovative solutions intended to transform care and improve  patients’ lives, today announced the completion of enrollment in the SAHARA Trial, a first of its kind outcomes study designed to evaluate whether an interventional dry eye procedure with the TearCare  System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of  twice daily Restasis® dry eye eyedrops (cyclosporine ophthalmic emulsion, 0.05%).